Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Personally I can't see countries accepting a majorly sub standard LFT once AffiDx is on the market and they see the accuracy differences, especially with all the negative press surrounding current LFTs .
governments need something that works and something the public trust to get the world back on its feet.
Innova upscaling their manufacturing capacity from current 450 million per month to 1.5 billion per month.
If the world is fast losing faith in the Innova tests and their reliability and there just so happens to be a near perfect reagent available that can be produced at the scale that they need Innova could well be looking to license AffiRx to keep their feet in the multi billion £ LFT market.
Not only giving them the most accurate test in the world using AffiRx but the longitivity that only the best LFTs will have.
This will most certainly be on Innova's radar and thoughts.
I definitely agree with excellent results of CV revenue is now nailed on ,the question now is how much? With potential for billions in revenue the LFT makes the current MC seem tiny.
With Ava6000 about to enter the clinic we are at a major turning point for the company with good early results doors can be unlocked for numerous other products as well with potential revenues of multi billions.
I think the big one the market is not taking into account is the importance of the recent licensing agreements with Astrea,Biokit and Point these companies have been evaluating our Affimers for their products rigourously for a long time before these deals are signed so these deals are concrete confirmation of the Affimer platform.
Not only that AS has hinted that numerous other large pharma are now evaluating our Affimers for their products. It will take many years for companies to get their products to market and for us to start receiving royalties but once at that point it is a constant stream of revenue with huge margins.
Affyxell is in its own right got the potential of a multi billion pound company.
The potential of TMAC aswell is again absolutely huge not only financially but for changing treatment and survival on cancer and other serious illnesses.
The revenue from our LFT is going to fast track alot of these products and put the other Ava programmes into the clinic which other wise would have been shelved due to funding.
No more fund raising or dilution isn't a bad place to be as an investor either.
So is Avacta the the cheapest it has ever been at these prices for where the company is?......... absolutely!!
And that is why I continue to top up most recent at 261 and 252.
Just to add to timsters reply:
"Avacta are a small company without the limitless resources of someone like Roche. Despite this they have created the most accurate LFT in the world. Roche have created a ****e one."
It's not just incredible that a small company like Avacta can produce a far superior LFT than the giants like Roche.
The amazing fact is we own the technology that makes it possible to have such high accuracy,
How many large -giant companies with massive budgets and many with loads of years experience in this field can not seem to get to the level of accuracy that Avacta can?
Avacta have never made a LFT before yet it took only 1 year to produce the most accurate LFT in the world.... it's not a coincidence ,That tells me that Avacta have something very special, to add to that keep in mind it only took 4 weeks to generate over 50 different Affimers specific to SARS-COV-2.
If CV data is as good or better than then clinical evaluation data it's safe to say we have the most accurate sensitive test /reagents in the UK( and one of the best globally)
We can easily produce 100 million Affimer reagents per month.
Why would Avacta not be supplying every single reagent for a sovereign test if it is infact the best.
A big part of this sovereign test is about Boris and about being British and having the best technology in the world and being a global leader testing and vaccines.
In my view if the company with the marginally best data can supply all reagents needed for a sovereign test then that's what the government will go with.
Skeleton, if the government is waiting for Avacta for the sovereign test they will have stock piled millions of tests or cassette's pipettes etc just waiting to insert the Affimer strip.all the time scales seem to be adding up to 1 conclusion............ Its us.
One thing everyone must remember this pandemic is not over,not by a long way and we must get our economy open before we get to a stage where large parts of it will never return.
Free tests for to get us through till after next winter will be a must for the government to safely reopen the economy.
The real risk of mutations that are more vaccine resistant is something that must be closely monitored for years to come as it has the potential to put us right back to the start and clearly no government can allow that to happen.
Mass testing will probably be scaled back after next winter but there will still be border crossing testing at airports docks etc so the markets will remain huge for a couple of years and only the best tests will survive and thrive into markets beyond covid.
For Avacta as we all know the LFT is only the funding for the programmes that I am truly excited about.
Jaylarc, I'm not that sure how it would work either but if Big Al and the team at Mologic think it's worth while there must be a benefit.
My thinking on it.... For false positives or negatives it could basically eliminate them as if there is a false reading for s there is a very slim chance it would also be false for N.
1. Because it's effectively 2 tests so odds of both being wrong are dramatically reduced.
2.because they are 2 different parts of the virus and any issue attaching to 1 might not apply to the other.
Again just guess work.
It is known that Mologics card technology is exceptional and I think that would help improve sensitivity so the idea their card tech for sensitivity and our Affimer tech for specicfity would be a perfect match but don't think their sensitivity was great in the figures they released ,so God knows.
Wilson it only took Avacta 4 weeks to generate about 50 different Affimers specific to SARS-COV -2.
So it is a very rapid process, what has taken time with our LFT is the fact we are making a diagnostic test from scratch, to be able to achieve this in a year is an incredible achievement. As big Al said recently it's easy to get a LFT working in the lab it takes time to refine it so there are 0 false negatives.
Alot depends on CV data ,if it were to be 99/100 then I can't see the point of trying to better the tests with using S and N if there were to be a severe mutation then simply generate new Affimers to attach to s on the varient. Again the different sampling methods for S and N might be an issue.
Matt I agree , my point being there won't be any hold backs on the development side as the the "test" cassette pipette etc have already been developed.
Your point about Mologic does make me wonder why have they only being able to produce a sub standard test given this is their niche.
With the s+n test with Mologic it's also important to remember that this will take a fraction of the time complete , big Al said in the most recent vox interview with Paul that the LFT is future proof and is very simple for future respiratory diseases for new Affimers just to be added.
I don't know how they would do it be it 2 strips 1s 1n or 1 strip with s&n but I don't think it would take that long to refine it.
With Affimers big Al would only ever have accepted 100% specificity after all that is one of there biggest trump hand over antibodies that that they are very specific.
And what a way too showcase them on the world stage.big Al has also stated that there has been alot of interest globally of the Affimer platform which I think means there are a number of large pharma evaluating Affimers for their products right now as we're point,astrea,biokit which have recently announced licensing agreements.
I think towards the end of the year and in to the start of next year we could be seeing vast licensing agreements from numourous large pharma,
I think that will also be the point where take over bids start coming in ( which I hope are firmly rejected)there are soo many advantages from using Affimers because they are so robust,the list of addressable markets for Affimers is absolutely enormous.
Then there's the precision platform again the implications are enormous and could change them way cancer is seen it might no longer be seen as a death sentence because of this platform.
And then the holy grail TMAC a mixture of the precision and Affimer platform completly next generation technology.
There is no other investment opportunity anything like this I won't be selling any shares or voting for any buy out unless the offers are multi 100 billions because that's where this company is heading in 5/10 years.
Affyxell will be multi billions in its self very soon
Oh and we have a world class LFT about to hit the market ;)
This is it this time timster.
The CV process can only take so long even with lower Infection levels.
There's no scientific problems no third party failings no goal posts being moved not this time one way or another we will finally have completed full CV ,can feel it in my bones it will be this week.